February 8, 2024
RESOLVE is MassChallenge’s annual showcase and awards event, bringing together founders, corporate partners and investors for demos and recognition across multiple tracks. In 2024 the showcase recognized 32 startups and awarded nearly $1 million in equity‑free cash and investment prizes. The event was held on February 8 2024 at the State Room in Boston. As a MassChallenge finalist to the Resolve summit, Vivifi was featured during the showcase—a buzzing floor where conversations moved quickly toward pilots and partnerships.
The RESOLVE floor concentrates the stakeholders who influence a device company’s entire arc—design, manufacturing, clinical operations and payer strategy—into one loop. Demonstrating our solution to this audience allowed us to gather feedback, accelerate our roadmap and identify collaborators who share our commitment to making BPH treatment less invasive and more sustainable. Being highlighted among MassChallenge alumni is a testament to the progress we’ve made since completing the accelerator.
MassChallenge is a global, zero‑equity startup accelerator that supports high‑impact entrepreneurs across industries. Its Boston‑based accelerator is known for nurturing early‑stage companies through mentorship, curriculum and connections. The RESOLVE event serves as an annual showcase and awards ceremony where participants demonstrate their innovations to investors and corporate partners. In 2024 the event recognized 32 startups and distributed nearly $1 million in equity‑free cash and investment prizes. The 2024 showcase was held at the State Room in Boston on February 8 2024
Vivifi Medical develops a minimally invasive therapy to reverse benign prostatic hyperplasia (BPH) by re‑establishing healthy blood flow. Our participation in MassChallenge provided us with mentors and investors who understand regulated medical devices. The RESOLVE highlight allowed us to reconnect with the MassChallenge community and share our progress toward clinical trials and commercialization.
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
